<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38937523</PMID><DateCompleted><Year>2024</Year><Month>06</Month><Day>27</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Jun</Month><Day>27</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Production of norovirus-, rotavirus-, and enterovirus-like particles in insect cells is simplified by plasmid-based expression.</ArticleTitle><Pagination><StartPage>14874</StartPage><MedlinePgn>14874</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">14874</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-65316-6</ELocationID><Abstract><AbstractText>Insect cells have long been the main expression host of many virus-like particles (VLP). VLPs resemble the respective viruses but are non-infectious. They are important in vaccine development and serve as safe model systems in virus research. Commonly, baculovirus expression vector system (BEVS) is used for VLP production. Here, we present an alternative, plasmid-based system for VLP expression, which offers distinct advantages: in contrast to BEVS, it avoids contamination by baculoviral particles and proteins, can maintain cell viability over the whole process, production of alphanodaviral particles will not be induced, and optimization of expression vectors and their ratios is simple. We compared the production of noro-, rota- and entero-VLP in the plasmid-based system to the standard process in BEVS. For noro- and entero-VLPs, similar yields could be achieved, whereas production of rota-VLP requires some further optimization. Nevertheless, in all cases, particles were formed, the expression process was simplified compared to BEVS and potential for the plasmid-based system was validated. This study demonstrates that plasmid-based transfection offers a viable option for production of noro-, rota- and entero-VLPs in insect cells.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lampinen</LastName><ForeName>Vili</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Virology and Vaccine Immunology, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Protein Dynamics, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gröhn</LastName><ForeName>Stina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Virology and Vaccine Immunology, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lehmler</LastName><ForeName>Nina</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Biotechnology, Institute for Biochemistry, Biotechnology and Bioinformatics, TU Braunschweig, Braunschweig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jartti</LastName><ForeName>Minne</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Virology and Vaccine Immunology, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hytönen</LastName><ForeName>Vesa P</ForeName><Initials>VP</Initials><AffiliationInfo><Affiliation>Protein Dynamics, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fimlab Laboratories, Tampere, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Schubert</LastName><ForeName>Maren</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biotechnology, Institute for Biochemistry, Biotechnology and Bioinformatics, TU Braunschweig, Braunschweig, Germany. maren.schubert@tu-braunschweig.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Hankaniemi</LastName><ForeName>Minna M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Virology and Vaccine Immunology, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland. minna.hankaniemi@tuni.fi.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>503667663</GrantID><Agency>DFG</Agency><Country /></Grant><Grant><GrantID>335870</GrantID><Agency>Research Council of Finland</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>06</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058425">Vaccines, Virus-Like Particle</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010957" MajorTopicYN="Y">Plasmids</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012401" MajorTopicYN="Y">Rotavirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029322" MajorTopicYN="Y">Norovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="N">Enterovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061987" MajorTopicYN="N">Sf9 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016367" MajorTopicYN="N">Baculoviridae</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005822" MajorTopicYN="N">Genetic Vectors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058425" MajorTopicYN="N">Vaccines, Virus-Like Particle</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007313" MajorTopicYN="N">Insecta</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Enterovirus</Keyword><Keyword MajorTopicYN="N">Insect cells</Keyword><Keyword MajorTopicYN="N">Norovirus</Keyword><Keyword MajorTopicYN="N">Protein expression</Keyword><Keyword MajorTopicYN="N">Rotavirus</Keyword><Keyword MajorTopicYN="N">VLP</Keyword><Keyword MajorTopicYN="N">Vaccine</Keyword><Keyword MajorTopicYN="N">Virus-like particle</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>28</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>6</Month><Day>28</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>6</Month><Day>27</Day><Hour>23</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>6</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38937523</ArticleId><ArticleId IdType="pmc">PMC11211442</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-65316-6</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-65316-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bachmann MF, Jennings GT. Vaccine delivery: A matter of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol. 2010;10:787–796. doi: 10.1038/nri2868.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2868</ArticleId><ArticleId IdType="pubmed">20948547</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinimaki S, et al. Combination of three virus-derived nanoparticles as a vaccine against enteric pathogens; enterovirus, norovirus and rotavirus. Vaccine. 2019 doi: 10.1016/j.vaccine.2019.09.072.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2019.09.072</ArticleId><ArticleId IdType="pubmed">31585726</ArticleId></ArticleIdList></Reference><Reference><Citation>Hankaniemi MM, et al. Formalin treatment increases the stability and immunogenicity of coxsackievirus B1 VLP vaccine. Antiviral Res. 2019 doi: 10.1016/j.antiviral.2019.104595.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2019.104595</ArticleId><ArticleId IdType="pubmed">31491431</ArticleId></ArticleIdList></Reference><Reference><Citation>Lampinen, V. et al. SpyTag/SpyCatcher display of influenza M2e peptide on norovirus-like particle provides stronger immunization than direct genetic fusion. Front. Cell. Infect. Microbiol.13, (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10323135</ArticleId><ArticleId IdType="pubmed">37424789</ArticleId></ArticleIdList></Reference><Reference><Citation>Haupt RM, Sings HL. The efficacy and safety of the quadrivalent human papillomavirus 6/11/16/18 vaccine gardasil. J. Adolesc. Health Off. Publ. Soc. Adolesc. Med. 2011;49:467–475. doi: 10.1016/j.jadohealth.2011.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jadohealth.2011.07.003</ArticleId><ArticleId IdType="pubmed">22018560</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiller JT, Castellsague X, Villa LL, Hildesheim A. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine. 2008;26 Suppl 1:53. doi: 10.1016/j.vaccine.2008.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2008.06.002</ArticleId><ArticleId IdType="pmc">PMC2631230</ArticleId><ArticleId IdType="pubmed">18847557</ArticleId></ArticleIdList></Reference><Reference><Citation>Vicente T, Roldão A, Peixoto C, Carrondo MJT, Alves PM. Large-scale production and purification of VLP-based vaccines. J. Invertebr. Pathol. 2011;107(Suppl):S42–48. doi: 10.1016/j.jip.2011.05.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jip.2011.05.004</ArticleId><ArticleId IdType="pmc">PMC7094596</ArticleId><ArticleId IdType="pubmed">21784230</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson CM, Aucoin MG, Kamen AA. Production of Virus-Like Particles for Vaccination. In: Murhammer DW, editor. Baculovirus and Insect Cell Expression Protocols. New York: Springer; 2016. pp. 299–315.</Citation><ArticleIdList><ArticleId IdType="pubmed">26820864</ArticleId></ArticleIdList></Reference><Reference><Citation>Correia R, Fernandes B, Alves PM, Carrondo MJT, Roldão A. Improving influenza HA-Vlps production in insect high five cells via adaptive laboratory evolution. Vaccines. 2020;8:589. doi: 10.3390/vaccines8040589.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines8040589</ArticleId><ArticleId IdType="pmc">PMC7711658</ArticleId><ArticleId IdType="pubmed">33036359</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamaji H, Konishi E. Production of Japanese encephalitis virus-like particles in insect cells. Bioengineered. 2013;4:438–442. doi: 10.4161/bioe.24514.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/bioe.24514</ArticleId><ArticleId IdType="pmc">PMC3937207</ArticleId><ArticleId IdType="pubmed">23639981</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai S, Zhang T, Zhang Y, Wang H, Deng F. Zika virus baculovirus-expressed virus-like particles induce neutralizing antibodies in mice. Virol. Sin. 2018;33:213–226. doi: 10.1007/s12250-018-0030-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12250-018-0030-5</ArticleId><ArticleId IdType="pmc">PMC6013542</ArticleId><ArticleId IdType="pubmed">29774519</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong Q, Liu J, Wei Y, Wei X. Application of baculovirus expression vector system (BEVS) in vaccine development. Vaccines. 2023;11:1218. doi: 10.3390/vaccines11071218.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11071218</ArticleId><ArticleId IdType="pmc">PMC10386281</ArticleId><ArticleId IdType="pubmed">37515034</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvalho SB, et al. Bioorthogonal strategy for bioprocessing of specific-site-functionalized enveloped influenza-virus-like particles. Bioconjug. Chem. 2016;27:2386–2399. doi: 10.1021/acs.bioconjchem.6b00372.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.bioconjchem.6b00372</ArticleId><ArticleId IdType="pmc">PMC5080633</ArticleId><ArticleId IdType="pubmed">27652605</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaves LCS, Ribeiro BM, Blissard GW. Production of GP64-free virus-like particles from baculovirus-infected insect cells. J. Gen. Virol. 2018;99:265–274. doi: 10.1099/jgv.0.001002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jgv.0.001002</ArticleId><ArticleId IdType="pubmed">29300162</ArticleId></ArticleIdList></Reference><Reference><Citation>Klaus T, et al. Overcoming inefficient secretion of recombinant VEGF-C in baculovirus expression vector system by simple purification of the protein from cell lysate. Protein Expr. Purif. 2015;110:151–158. doi: 10.1016/j.pep.2015.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pep.2015.03.001</ArticleId><ArticleId IdType="pubmed">25758709</ArticleId></ArticleIdList></Reference><Reference><Citation>Yun E-Y, et al. Changes in cellular secretory processing during baculovirus infection. Biotechnol. Lett. 2005;27:1041–1045. doi: 10.1007/s10529-005-8108-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10529-005-8108-1</ArticleId><ArticleId IdType="pubmed">16132851</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y-R, et al. Transcriptome responses of the host trichoplusia ni to infection by the baculovirus Autographa californica multiple nucleopolyhedrovirus. J. Virol. 2014;88:13781–13797. doi: 10.1128/JVI.02243-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02243-14</ArticleId><ArticleId IdType="pmc">PMC4248991</ArticleId><ArticleId IdType="pubmed">25231311</ArticleId></ArticleIdList></Reference><Reference><Citation>Li T-C, Scotti PD, Miyamura T, Takeda N. Latent infection of a new alphanodavirus in an insect cell line. J. Virol. 2007;81:10890–10896. doi: 10.1128/JVI.00807-07.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00807-07</ArticleId><ArticleId IdType="pmc">PMC2045576</ArticleId><ArticleId IdType="pubmed">17686877</ArticleId></ArticleIdList></Reference><Reference><Citation>Mena JA, Ramírez OT, Palomares LA. Population kinetics during simultaneous infection of insect cells with two different recombinant baculoviruses for the production of rotavirus-like particles. BMC Biotechnol. 2007;7:39. doi: 10.1186/1472-6750-7-39.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1472-6750-7-39</ArticleId><ArticleId IdType="pmc">PMC1929069</ArticleId><ArticleId IdType="pubmed">17610729</ArticleId></ArticleIdList></Reference><Reference><Citation>Sokolenko S, et al. Co-expression vs. co-infection using baculovirus expression vectors in insect cell culture: Benefits and drawbacks. Biotechnol. Adv. 2012;30:766–781. doi: 10.1016/j.biotechadv.2012.01.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biotechadv.2012.01.009</ArticleId><ArticleId IdType="pmc">PMC7132753</ArticleId><ArticleId IdType="pubmed">22297133</ArticleId></ArticleIdList></Reference><Reference><Citation>Bieniossek C, Imasaki T, Takagi Y, Berger I. MultiBac: Expanding the research toolbox for multiprotein complexes. Trends Biochem. Sci. 2012;37:49–57. doi: 10.1016/j.tibs.2011.10.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tibs.2011.10.005</ArticleId><ArticleId IdType="pmc">PMC7127121</ArticleId><ArticleId IdType="pubmed">22154230</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaron M, et al. Baculovirus-free SARS-CoV-2 virus-like particle production in insect cells for rapid neutralization assessment. Viruses. 2022;14:2087. doi: 10.3390/v14102087.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14102087</ArticleId><ArticleId IdType="pmc">PMC9606917</ArticleId><ArticleId IdType="pubmed">36298643</ArticleId></ArticleIdList></Reference><Reference><Citation>Puente-Massaguer E, et al. PEI-mediated transient transfection of high five cells at bioreactor scale for HIV-1 VLP production. Nanomaterials. 2020;10:1580. doi: 10.3390/nano10081580.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nano10081580</ArticleId><ArticleId IdType="pmc">PMC7466501</ArticleId><ArticleId IdType="pubmed">32806511</ArticleId></ArticleIdList></Reference><Reference><Citation>Korn J, et al. Baculovirus-free insect cell expression system for high yield antibody and antigen production. Sci. Rep. 2020;10:21393. doi: 10.1038/s41598-020-78425-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-78425-9</ArticleId><ArticleId IdType="pmc">PMC7721901</ArticleId><ArticleId IdType="pubmed">33288836</ArticleId></ArticleIdList></Reference><Reference><Citation>Rackoff LA, Bok K, Green KY, Kapikian AZ. Epidemiology and evolution of rotaviruses and noroviruses from an archival WHO global study in children (1976–79) with implications for vaccine design. PLOS ONE. 2013;8:e59394. doi: 10.1371/journal.pone.0059394.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0059394</ArticleId><ArticleId IdType="pmc">PMC3607611</ArticleId><ArticleId IdType="pubmed">23536875</ArticleId></ArticleIdList></Reference><Reference><Citation>Atmar RL, Estes MK. The Epidemiologic and clinical importance of norovirus infection. Gastroenterol. Clin. North Am. 2006;35:275–290. doi: 10.1016/j.gtc.2006.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gtc.2006.03.001</ArticleId><ArticleId IdType="pubmed">16880066</ArticleId></ArticleIdList></Reference><Reference><Citation>Koho T, et al. Purification of norovirus-like particles (VLPs) by ion exchange chromatography. J. Virol. Methods. 2012;181:6–11. doi: 10.1016/j.jviromet.2012.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2012.01.003</ArticleId><ArticleId IdType="pubmed">22265819</ArticleId></ArticleIdList></Reference><Reference><Citation>Lampinen V, et al. Modular vaccine platform based on the norovirus-like particle. J. Nanobiotechnol. 2021;19:20–25. doi: 10.1186/s12951-021-00772-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12951-021-00772-0</ArticleId><ArticleId IdType="pmc">PMC7815183</ArticleId><ArticleId IdType="pubmed">33468139</ArticleId></ArticleIdList></Reference><Reference><Citation>Blazevic V, Lappalainen S, Nurminen K, Huhti L, Vesikari T. Norovirus VLPs and rotavirus VP6 protein as combined vaccine for childhood gastroenteritis. Vaccine. 2011;29:8126–8133. doi: 10.1016/j.vaccine.2011.08.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.08.026</ArticleId><ArticleId IdType="pubmed">21854823</ArticleId></ArticleIdList></Reference><Reference><Citation>Tate JE, et al. 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: A systematic review and meta-analysis. Lancet Infect. Dis. 2012;12:136–141. doi: 10.1016/S1473-3099(11)70253-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(11)70253-5</ArticleId><ArticleId IdType="pubmed">22030330</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotavirus vaccines: WHO position paper—July 2021. https://www.who.int/publications-detail-redirect/WHO-WER9628.</Citation></Reference><Reference><Citation>Drory Y, et al. Sudden unexpected death in persons less than 40 years of age. Am. J. Cardiol. 1991;68:1388–1392. doi: 10.1016/0002-9149(91)90251-F.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0002-9149(91)90251-F</ArticleId><ArticleId IdType="pubmed">1951130</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarez JA, Wilkinson JD, Lipshultz SE. Outcome predictors for pediatric dilated cardiomyopathy: A systematic review. Prog. Pediatr. Cardiol. 2007;23:25–32. doi: 10.1016/j.ppedcard.2007.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ppedcard.2007.05.009</ArticleId><ArticleId IdType="pmc">PMC2729918</ArticleId><ArticleId IdType="pubmed">19701490</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunization Systems Management Group of the Global Polio Eradication Initiative. Introduction of inactivated poliovirus vaccine and switch from trivalent to bivalent oral poliovirus vaccine—worldwide, 2013–2016. MMWR Morb. Mortal. Wkly. Rep.64, 699–702 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4584682</ArticleId><ArticleId IdType="pubmed">26135591</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampton, L. M. Cessation of trivalent oral poliovirus vaccine and introduction of inactivated poliovirus vaccine—worldwide, 2016. MMWR Morb. Mortal. Wkly. Rep.65, (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27606675</ArticleId></ArticleIdList></Reference><Reference><Citation>Enterovirus 71. https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/vaccine-standardization/enterovirus-71.</Citation></Reference><Reference><Citation>Koho T, et al. Coxsackievirus B3 VLPs purified by ion exchange chromatography elicit strong immune responses in mice. Antiviral Res. 2014;104:93–101. doi: 10.1016/j.antiviral.2014.01.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2014.01.013</ArticleId><ArticleId IdType="pubmed">24485896</ArticleId></ArticleIdList></Reference><Reference><Citation>Hankaniemi MM, et al. Structural insight into CVB3-VLP non-adjuvanted vaccine. Microorganisms. 2020 doi: 10.3390/microorganisms8091287.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms8091287</ArticleId><ArticleId IdType="pmc">PMC7565060</ArticleId><ArticleId IdType="pubmed">32846899</ArticleId></ArticleIdList></Reference><Reference><Citation>Koho T, et al. His-tagged norovirus-like particles: A versatile platform for cellular delivery and surface display. Eur. J. Pharm. Biopharm. 2015;96:22–31. doi: 10.1016/j.ejpb.2015.07.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejpb.2015.07.002</ArticleId><ArticleId IdType="pubmed">26170162</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinimäki S, et al. Antigenicity and immunogenicity of HA2 and M2e influenza virus antigens conjugated to norovirus-like, VP1 capsid-based particles by the SpyTag/SpyCatcher technology. Virology. 2022;566:89–97. doi: 10.1016/j.virol.2021.12.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2021.12.001</ArticleId><ArticleId IdType="pubmed">34894525</ArticleId></ArticleIdList></Reference><Reference><Citation>Lampinen V, et al. Modular vaccine platform based on the norovirus-like particle. J. Nanobiotechnology. 2021;19:25. doi: 10.1186/s12951-021-00772-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12951-021-00772-0</ArticleId><ArticleId IdType="pmc">PMC7815183</ArticleId><ArticleId IdType="pubmed">33468139</ArticleId></ArticleIdList></Reference><Reference><Citation>Palomares LA, Ramirez OT. Challenges for the production of virus-like particles in insect cells: The case of rotavirus-like particles. Biochem. Eng. J. 2009;45:158–167. doi: 10.1016/j.bej.2009.02.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bej.2009.02.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Lappalainen S, Vesikari T, Blazevic V. Simple and efficient ultrafiltration method for purification of rotavirus VP6 oligomeric proteins. Arch. Virol. 2016;161:3219–3223. doi: 10.1007/s00705-016-2991-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-016-2991-8</ArticleId><ArticleId IdType="pubmed">27518400</ArticleId></ArticleIdList></Reference><Reference><Citation>Lepault J, et al. Structural polymorphism of the major capsid protein of rotavirus. Embo J. 2001;20:1498–1507. doi: 10.1093/emboj/20.7.1498.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/emboj/20.7.1498</ArticleId><ArticleId IdType="pmc">PMC145494</ArticleId><ArticleId IdType="pubmed">11285214</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamminen K, Heinimaki S, Grohn S, Blazevic V. Internalization and antigen presentation by mouse dendritic cells of rotavirus VP6 preparations differing in nanostructure. Mol. Immunol. 2020;123:26–31. doi: 10.1016/j.molimm.2020.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2020.04.001</ArticleId><ArticleId IdType="pubmed">32388275</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinimäki S, Tamminen K, Hytönen VP, Malm M, Blazevic V. Rotavirus inner capsid VP6 acts as an adjuvant in formulations with particulate antigens only. Vaccines. 2020;8:365. doi: 10.3390/vaccines8030365.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines8030365</ArticleId><ArticleId IdType="pmc">PMC7565724</ArticleId><ArticleId IdType="pubmed">32645976</ArticleId></ArticleIdList></Reference><Reference><Citation>Hitchman RB, et al. Genetic modification of a baculovirus vector for increased expression in insect cells. Cell Biol. Toxicol. 2010;26:57–68. doi: 10.1007/s10565-009-9133-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10565-009-9133-y</ArticleId><ArticleId IdType="pubmed">19655260</ArticleId></ArticleIdList></Reference><Reference><Citation>Krammer F, et al. Trichoplusia ni cells (High Five) are highly efficient for the production of influenza A virus-like particles: a comparison of two insect cell lines as production platforms for influenza vaccines. Mol. Biotechnol. 2010;45:226–234. doi: 10.1007/s12033-010-9268-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12033-010-9268-3</ArticleId><ArticleId IdType="pmc">PMC4388404</ArticleId><ArticleId IdType="pubmed">20300881</ArticleId></ArticleIdList></Reference><Reference><Citation>Hankaniemi MM, et al. Optimized production and purification of Coxsackievirus B1 vaccine and its preclinical evaluation in a mouse model. Vaccine. 2017;35:3718–3725. doi: 10.1016/j.vaccine.2017.05.057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2017.05.057</ArticleId><ArticleId IdType="pubmed">28579231</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinimäki S, et al. Combination of three virus-derived nanoparticles as a vaccine against enteric pathogens; enterovirus, norovirus and rotavirus. Vaccine. 2019;37:7509–7518. doi: 10.1016/j.vaccine.2019.09.072.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2019.09.072</ArticleId><ArticleId IdType="pubmed">31585726</ArticleId></ArticleIdList></Reference><Reference><Citation>Bleckmann M, et al. Identifying parameters to improve the reproducibility of transient gene expression in High Five cells. PLoS ONE. 2019;14:e0217878. doi: 10.1371/journal.pone.0217878.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0217878</ArticleId><ArticleId IdType="pmc">PMC6553862</ArticleId><ArticleId IdType="pubmed">31170233</ArticleId></ArticleIdList></Reference><Reference><Citation>Hausjell CS, Ernst W, Grünwald-Gruber C, Arcalis E, Grabherr R. Quantitative proteomic analysis of extracellular vesicles in response to baculovirus infection of a Trichoplusia ni cell line. PloS One. 2023;18:e0281060. doi: 10.1371/journal.pone.0281060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0281060</ArticleId><ArticleId IdType="pmc">PMC9886248</ArticleId><ArticleId IdType="pubmed">36716331</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato T, Yui M, Deo VK, Park EY. Development of rous sarcoma virus-like particles displaying hCC49 scFv for specific targeted drug delivery to human colon carcinoma cells. Pharm. Res. 2015;32:3699–3707. doi: 10.1007/s11095-015-1730-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11095-015-1730-2</ArticleId><ArticleId IdType="pubmed">26047779</ArticleId></ArticleIdList></Reference><Reference><Citation>Bleckmann M, et al. Genomic analysis and isolation of RNA polymerase II dependent promoters from Spodoptera frugiperda. PloS One. 2015;10:e0132898. doi: 10.1371/journal.pone.0132898.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0132898</ArticleId><ArticleId IdType="pmc">PMC4532503</ArticleId><ArticleId IdType="pubmed">26263512</ArticleId></ArticleIdList></Reference><Reference><Citation>Rueden CT, et al. Image J2: ImageJ for the next generation of scientific image data. BMC Bioinformatics. 2017;18:529. doi: 10.1186/s12859-017-1934-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12859-017-1934-z</ArticleId><ArticleId IdType="pmc">PMC5708080</ArticleId><ArticleId IdType="pubmed">29187165</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>